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of sixteen countries from the region according to different criteria: characteristics, 
quality (using Drummond’s checklist), use of local data, addressed inputs limita-
tion and results transferability. Results: Economic evaluations are used in CEE 
countries for informing decision making, while critically considering methodology, 
quality and study’s reliability. Experts acknowledged limited generalizability of study 
results both between and within geographic regions. Meanwhile, despite these con-
straints, facing limited health technology assessment (HTA) capacity experts were 
still using foreign evidence. At the same time, the usefulness of studies published in 
CEE and former Soviet countries to inform their decision making is limited because 
of insufficient transparency in reporting, unaddressed uncertainty, limited insight on 
inputs and transferability of results. Although local costs, baseline risk and resource 
use data are required, experts accept evidence originating from health care settings 
outside CEE and former Soviet countries regarding relative effect and utilities val-
ues. ConClusions: HTA priority setting and transferability assessment of economic 
evidence are important issue in health care decision making in CEE and former Soviet 
countries, since HTA research capacity is limited and local evidence is scarce. For this 
purpose, quality, transparency, and transferability should be addressed explicitly in 
published economic evaluations originating from CEE and former Soviet countries.
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BACkgRound: The Department of Science and Technology (DECIT) at the Ministry 
of Health (MoH), since 2003, has financed studies to support demands from 
the MoH technical areas regarding the decision making process about health 
technologies. oBjeCtives: To analyze DECIT performance in financed Health 
Technology Assessment (HTA) studies to improve the capacity building of HTA in 
Brazil. Methods: A retrospective descriptive study based on the analysis of docu-
ments and official records built in a single database in Excel containing the studies 
promoted by DECIT from 2003 to November 27, 2013. The variables pre-classified 
and collected from Brazilian Network for Health Technology Assessment’s database, 
SISREBRATS, were revised by two reviewers and conferred or supplemented with data 
from the Database of Health Research, Annual Reports Management by DECIT, and 
Final Reports and Cooperation Agreements by co-financier partners. Results: 284 
HTA projects were financed entirety for R$ 25 million (± R$ 1,69 million) between 2003 
and 2013. The average value financed was R$ 346 thousand and the average bias was 
± RS 61 thousand. Of these, 57% (162/284) are pharmacotherapy; and 35% (99/248) are 
systematic reviews. The majority of the studies 58% (165/284) were financed by MoH 
calls in years 2005 to 2010 and contributed to 110 masters and doctors conclusions in 
HTA landfield. ConClusions: These numbers show despite the HTA culture in Brazil 
having been in its initial stage, DECIT is increasing its capacity to respond to demands 
with a variety of studies types, specily in pharmacotherapy. However, evaluation 
demands do not always correspond to health needs of promotion and prevention.
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oBjeCtives: Since January 2011, pharmaceutical manufacturers are obliged to sub-
mit dossiers presenting benefits over comparative treatment when launching new 
products in the German pharmaceutical market. These dossiers are usually evalu-
ated by the Institute for Quality and Efficiency in Health Care (IQWiG). Based on the 
dossier, the IQWiG’s evaluation and a subsequent hearing process, the Federal Joint 
Committee (G-BA) decides on additional therapeutic benefit related to mortality, 
morbidity, quality of life (QoL) and side effects. As QoL is among the more contested 
of these criteria and remains comparably unspecified, this qualitative study’s aim 
was to analyze definitions and the role of QoL in early assessments of benefit (EAB) 
in Germany. Methods: As most of the documents are freely available on the G-BA’s 
website, this study included all relevant documents of the first completed 66 assess-
ments (11.2011-12.2013). We conducted a qualitative content analysis screening the 
dossiers, IQWiG evaluations, G-BA decisions and the protocols of the oral hearing for 
relevant links to QoL and synonyms. In a process of independent analysis and joint 
consensus building by two researchers, relevant text passages were extracted and 
reduced to key content on the term’s usage. During analysis, a system of codes was 
developed accounting for a wide variety of recurring QoL-related definitions and 
references to its importance. Results: Even though key players did not necessarily 
share the same QoL-definition, the concept’s relative importance was highlighted in 
numerous references. G-BA decisions criticize the lack of or the inadequate presen-
tation of QoL data in the manufacturer’s dossiers. G-BA and IQWiG apply a narrow 
understanding of QoL, while manufacturers failed to establish wider notions of QoL 
linking factors such as patient satisfaction to the concept. ConClusions: QoL in a 
particular sense is of pivotal importance in Germany’s early assessment of benefit. 
The demand for reliable QoL data is growing.
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oBjeCtives: Advanced-therapy medicinal products (ATMPs), such as gene therapy, 
cell therapy and tissue engineering are a new class of medicines in the EU. ATMPs 
offer prospects in prevention and treatment of fatal and/or chronic debilitating 
diseases where no effective treatments exist. However, with complicated mecha-
nisms of actions and benefits often being anticipated in the longer term, it is chal-
lenging to demonstrate hard clinical evidence and create robust cost-effectiveness 
models that Payers have come to expect at the launch of pharmaceuticals. Thus, 
manufacturers face difficulties when negotiating the price for ATMPs and may not 
be able to realize their full potential. This paper aims to use case studies of ATMPs 
launched in EU5 to outline access pathways and review the clinical and economic 
evidence requirements. Methods: Secondary research identified ATMP approv-
als since 2008 and a framework was created to develop hypotheses on clinical 
and economic evidence requirements, considering alternative routes to market. 
Hypotheses were then validated during in-depth interviews with key stakeholders 
across EU5. Results: Payers are yet to be convinced about the full benefit of ATMPs 
and are reluctant to pay premium prices if they are not sure about long-term effi-
cacy and safety. Additionally, in their cost-benefit analyses, Payers tend to consider 
only the direct costs associated with a condition, ignoring broader societal benefits 
and savings in the long run. Therefore, price negotiations are sometimes lengthy. 
Risk sharing and novel payment-by-result schemes are often agreed to mitigate 
risks. ConClusions: Payers are not yet familiar with the potential value of ATMPs, 
and, in most cases specific evaluation criteria don’t exist. Manufacturers need to 
invest in educating Payers on the huge differences between ATMPs and traditional 
therapies, particularly to show that manufacturing costs are substantial, and work 
together to identify relevant measures for clinical and economic evaluations of 
this new therapy class.
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oBjeCtives: The Objectives are to present the characteristics of the quick-HTA 
started in June 2013 and to show the Results of the first quick-HTA process in 
Romania. Methods: The health care context and the Romanian legislation cov-
ering HTA were studied by considering: the reasons behind HTA introduction, the 
key stakeholders and the HTA process. A critical appraisal was done covering public 
HTA reports and the decisions taken by the Ministry of Health (MofH). Results: 
The introduction of quick-HTA began mid-June 2013 when MofH released the leg-
islation and the HTA Unit started receiving dossiers for new drugs/indications. The 
HTA model was based on a “score-card” system with 6 criteria: HAS (France) opinion, 
NICE/SMC/AWMSG (UK) opinion, the number of EU countries with reimbursement, 
relative efficacy, relative safety and relative patient-reported-outcomes (PRO), but no 
role of budget impact. From June to December 2013, 167 HTA dossiers were evaluated 
by the HTA Unit with an acceptance rate of about 80%. Most of the drugs accepted for 
reimbursement were oncological (23%); other main therapeutic areas were diabetes 
with 16 drugs/indications receiving positive evaluations, rheumatology (14), onco-
haematology (8) and neurology (7). The HTA included also biosimilars, all 4 of them 
receiving positive decisions. Unfortunately, early 2014, the new Government abrogated 
this HTA legislation and the already-published HTA reports, claiming that the process 
didn’t mentioned the criteria for de-listing reimbursed drugs nor the budget impact, 
within HTA reports. Moreover, the HTA process was moved into the responsibility of 
the National Agency for Drugs. ConClusions: The implementation of the quick-HTA 
in Romania took a good start, using a mixture of information, from benefits and cost-
effectiveness in other countries, to relative effectiveness, safety and PRO. However, 
the lack of consideration for the local context and the political disagreements led to 
a temporary suspension of this quick-HTA process in Romania.
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oBjeCtives: The objective of the study was to provide an external assessment 
of recent HTA institutionalization in Brazil, and identify a set of lessons learned 
potentially applicable to BRICS States. Methods: This research is based on a quan-
titative and qualitative assessment. A literature survey between 2000 and 2014 was 
conducted in English, Spanish and Portuguese in PubMed/Medline, Science Direct, 
LILACS and SciELO. Epidemiological and socio-economic data was retrieved from 
national health accounts as well as WHO/PAHO, OECD and World Bank. For the 
Brazilian National Committee for Incorporation of Technologies (CONITEC), avail-
able reports on the incorporation of medicines into the National Unified System 
(SUS) for the first two years of operation (2012 and 2013) were analyzed. A matrix 
containing quantitative and qualitative criteria was elaborated to analyze reports 
by the outcome of decision, therapeutic class, author (s) of the request and public 
consultation. Results: A total of 92 available CONITEC reports for 2012 (n= 38, 33 
for medicines) and 2013 (n= 54, 42 for medicines) were analyzed. 45% of reports on 
medicines recommended incorporation into the SUS. Most of the positive recom-
mendations were clearly related to public health priorities as identified by the gov-
ernment, translating a strong commitment for improved access to medicines within 
the SUS i.e. anti-cancer drugs. Overall, the creation of the CONITEC represents a 
substantial step toward the institutionalization of HTA, with more transparency 
and accountability in decision-making processes, considering ethical, organiza-
tional, social, and legal aspects. ConClusions: Whereas lowest in Russia, India 
and South Africa, and at a transitional stage in China, Brazil has a comparable 
degree of institutionalization of HTA as countries with a long-lasting HTA experi-
ence. A best-practice assessment in the area of HTA within the BRICS has still to be 
elaborated. Transferability of lessons learned might be a strong tool for improving 
HTA development within the BRICS.
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oBjeCtives: Gemeinsame Bundesausschuss (G-BA) states that it assesses addi-
tional benefit strictly on clinical grounds, but it also requires that manufacturers 
submit drug and comparator costs. This raises the possibility that G-BA’s assessment 
might be influenced by price, possibly to provide leverage during subsequent price 
negotiations. This research tests the hypothesis that high cost drugs (relative to 
the comparator) are more likely to receive poor benefit assessments. Methods: 
The following variables were collected from the Federal Gazette publication or the 
“Beschluss” document: additional benefit assessment, annual cost per patient of 
drug and comparator, and estimated target population. The Scottish Medicines 
Consortium (SMC) clinical rationale for the same drugs and indications were col-
lected to control for clinical efficacy. After excluding orphan drugs, reviews using 
best supportive care comparators, and reviews without SMC reviews, 58 reviews 
remained for analysis. G-BA’s additional benefit assessments were ranked from 
least benefit to most. The influence of drug cost relative to the comparator on the 
G-BA assessment was estimated via an ordered logit model. The model also included 
controls for the (log) size of the target population and clinical efficacy (SMC’s clinical 
assessment). Results: An increase in the cost difference between the drug and the 
comparator is estimated to result in a modest, statistically significant increase in the 
odds of receiving an additional benefit assessment greater than a “no additional 
benefit” assessment. ConClusions: Our results are inconsistent with the alterna-
tive hypothesis that G-BA is strategically discounting its assessment of relatively 
high cost drugs. The positive estimated relationship is consistent with manufactur-
ers’ setting higher prices for more beneficial drugs (The data available provide no 
way to statistically account for this plausible source of endogeneity). Our results 
provide no support for rejecting the null hypothesis that G-BA assesses added ben-
efit independently of drug cost.
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oBjeCtives: The aim of this study was to assess the development of HTA in 
Turkey. Methods: In this regard, organization structures of the Ministry of Health 
(MoH) and Social Security Institution (SSI) and presentations of first HTA meet-
ing held in April 2014 have been analyzed. Results: There are three main HTA 
agencies in Turkey. One is under the payer institution called SSI. The HTA com-
mittee of SSI assesses all the new health technologies to define whether they will 
be reimbursed or not. In other words, this committee is the major decisive HTA 
committee. Other two HTA committees are under the MoH. One of these is under 
the General Directorate of Pharmaceuticals and Medical Devices. This committee 
assesses certain drugs which are specifically asked to be evaluated by the SSI, MoH 
or other Ministries. One of the projects completed by this committee is the evalua-
tion of top 100 selling drugs according to the effect of price, regulation, market and 
qualitative characteristics of drugs. The second committee of the MoH is under 
the General Directorate of Health Research. This committee assesses more general 
issues like obesity, KOAH etc., instead of certain health technologies and publishes 
national reports. One of the reports published by this committee was the impor-
tance of obesity surgery in the treatment of obesity. In addition to all these three 
committees, HTA studies also being carried out by a MoH hospital called Ankara 
Numune Training and Research Hospital (ANHTA). They have been working on hos-
pital based HTA. ConClusions: Despite valuable studies being conducted as stated 
above, HTA is still in its infancy in Turkey and compared to other EU countries like 
Germany, UK etc. there is not an autonomous HTA agency. There are more than one 
committee, working on different aspects of health technology assessment under 
the supervision of government.
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BACkgRound: Defining health technology assessment priorities has been a chal-
lenge for the Department of Science and Technology who adopted a prioritiza-
tion criteria strategy (epidemiologic relevance, services/policy relevance, state of 
the art, operational feasibility and social demand) for demands from MoH tech-
nical areas. However, evaluation demands do not always correspond to health 
needs. oBjeCtives: To analyze the relationship between projects financed from 2003 
to 2013 and disease burdens in Brazil. Methods: Systematization of the summaries 
from financed projects through searches in the information from www.saude.gov.br/
rebrats and http://pesquisasaude.saude.gov.br/bdgdecit/ and categorization according 
to the twenty sub-groups of diseases and injuries of disease burden (Dalys) research 
in Brazil (SHARMM ET al, 1998). Results: 284 HTA projects financed between 2003 
and 2013. Of these, 24% (68/284) apply to the twenty main causes of loss of life years 
by premature death or incapacitation (Dalys, 1998). The first three largest are equal 
to 15% – diabetes, coronary ischemia, acute myocardial infarction, angina, cerebral 
infarction and stroke– corresponded to 13% of the (37/284) projects. ConClusions: 
The percentage found allows for the questioning of the prioritization starting point 
where the criteria are applied to subjects selected due to external influence and 
pressure from the market and not necessarily based on the needs impacting the 
population’s health. Uniting the two dimensions while also taking into account the 
strategic innovations in order to prioritize and finance assessment will be important 
for health systems sustainability.
PHP246
firsT exPeriences WiTH THe neW TesTing examinaTiOn anD TreaTmenT: 
meTHODs in germanY: is THis a neW amnOg clOne?
Bonduelle D.1, Eheberg D.2, Plantoer S.1
1IMS HEALTH GmbH & Co. OHG, Munich, Germany, 2IMS HEALTH, Munich, Germany
oBjeCtives: In a new regulation the Federal Joint Committee (G-BA) can pass 
directives for testing examination and treatment methods with not yet suffi-
ciently proven benefit, but which show potential as essential treatment alter-
natives (§137e SGB V). The objective of the present study was to compare the 
requirements for a successful application with the existing AMNOG (Law on the 
Reorganization of the Pharmaceutical Market) HTA requirements in Germany. 
The applicants must submit valid data on the potential of the method in ques-
tion, among other requirements. In one of the first applications in Germany, 
done by the authors, we see a lot of parallels with the HTA process for drugs but 
also a lot of uncertainties. Methods: We compared the requirements of the 
IQWIG Methodology paper 4.2 and the G-BA rules of procedure for the early ben-
efit assessment for medical drugs (§35a SGB V) with the new potential analysis 
for examination and treatment methods. This analysis was made for different 
criteria’s like study and endpoint design, certainty of results of the studies and 
others. We used our business case as template to extract the key-learning’s 
and identify the pitfalls in the new process. Results: The new legislation will 
have a strong impact on the study design and evidence to show the potential 
of new examination and treatment methods as essential treatment alterna-
tives. A lot of evaluation criteria’s came from the drug assessments but are 
hardly applicable to proof the potential of new examination and treatment 
methods. ConClusions: The legislation uses parts of classic HTA assessment 
on medical drugs to evaluate the potential of new examination and treatment 
methods. In most cases this is not possible and will decrease the level of evi-
dence of available clinical data for new examination and treatment methods 
due to grey zones and loopholes in the legislation.
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oBjeCtives: This study aims to assess the existence of a correlation between 
the applicability of end-of-life treatment criteria and the likelihood of NICE 
requiring a Patient Access Scheme (PAS) to recommend the treatment for 
funding. Methods: A review of all patient access schemes in existence as 
of March 2014 for NICE-recommended drugs was conducted to assess how 
many of those were for medicines which met the end-of-life treatment criteria 
and whether the supplementary criteria for end-of-life treatments had any 
bearing on the final NICE recommendation. Results: In total 42 PAS were 
identified. Of those, end-of-life treatment criteria were met and had bearing 
on the final NICE guidance in 7 cases (16.7%). End-of-life treatment criteria 
were considered but were not met in full in the case of 3 NICE reviews (in one 
of the three NICE considered that end-of-life criteria were not met in another 
review, even though the manufacturer had not applied for those criteria to 
be considered in the present review). End-of-life treatment criteria were also 
considered for one additional review where they were a focal point of the manu-
facturer appeal against the NICE guidance. In one additional case, end-of-life 
criteria were applied for but had no bearing on the final NICE guidance as the 
cost-effectiveness threshold was met without the application of special con-
siderations. ConClusions: Given the high cost of drugs meeting end-of-life 
criteria (most of which are for oncology indications), as expected, many of them 
are subject to a PAS in the UK. However, the opposite correlation does not hold 
true - i.e., the requirement for a PAS in the UK is not restricted to end-of-life 
treatments.
HealTH care use & POlicY sTuDies – Patient registries &  
Post-marketing studies
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oBjeCtives: At market entry, there usually is uncertainty regarding a new medi-
cine’s benefit-risk profile. Therefore, regulatory authorities may request additional 
pharmacovigilance (PhV) activities. Regulatory Authorities can request a Post-
Authorisation Safety Study (PASS) such as a registry, database study, survey, or 
clinical trial to reduce the uncertainty regarding certain safety risks. We aimed to 
assess the costs and effects of PASS for centrally approved new active substances 
(NAS) in Europe in 2007. Methods: We compared two scenarios for all NAS (n= 47): 
(1) Full regulation: routine PhV activities (spontaneous adverse drug reaction (ADR) 
reporting) with additional PASSs for some NAS; (2) Limited regulation: only routine 
PhV activities. For a follow-up period of six years after marketing we assessed the 
safety-related labeling changes for NAS and identified the source of these changes 
(PASS, spontaneous ADR reporting or other). Data on labeling changes was extracted 
from the European Medicines Agency’s website. A survey among pharmaceutical 
companies was used to estimate the costs of all requested PASSs. Results: For 
23 of the 47 NAS, at least one PASS (33 PASS in total) was requested in 2007. After 
six years, on average 8.1 safety-related labeling changes were identified per NAS. 
Requested PASS were the source of ~4% of all cases of new safety information identi-
fied. The total estimated costs of the 33 requested PASS were between € 50 and € 150 
million. ConClusions: For the 2007 cohort of NAS approved in Europe, the total 
costs of all requested PASS were substantial and yet these PASS contributed to the 
identification of only 4% of all new safety information identified post-marketing 
for NAS. However, PASS primarily aim to reduce uncertainty regarding safety risks 
and the (societal) value of this uncertainty reduction might not fully be captured 
by assessing health effects alone.
